Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to help women with bladder leakage

NCT ID NCT05828979

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new artificial urinary sphincter device in 6 women with stress incontinence (leaking urine during activity). The goal is to see if the device is safe and works well. Researchers will check how many devices need to be removed or fixed, and if pad weight tests show improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged \>18 years old * Female patient * Cognitively able and willing to sign an informed consent * Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months * Use of medically acceptable contraception, if of childbearing potential * Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints * Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator * Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator * Life expectancy ≥ 5 years as assessed by the investigator * Affiliated with an appropriate social security system * Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, ACT, etc. (excluding other AUS devices) * Negative urine culture prior to the procedure * Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests * Clinically insignificant post-void residual (PVR) urine defined as \< 50 ml and/or no greater than 10% of the voided volume * Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary Exclusion Criteria: * Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months * Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing her from giving her consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn her consent) * Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions * Pregnant patient, or patient planning pregnancy during the study duration * Patient presenting one or several contraindications of the device * Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes * Known allergy to UroMems eAUS implantable components * History of pelvic irradiation (external beam therapy or brachytherapy) * Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of \>12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of \>9% (75 mmol/mol) over the preceding 3 months * History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value \>70 * Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured * Previous AUS implant * Currently has another Active Implantable Medical Device (AIMD) implanted * Urge incontinence, mixed incontinence (MI) with a predominant urgency component * Overflow urinary incontinence * Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods * Abnormal or poor bladder compliance defined as being \<30 ml/ cm H2O * Bladder neck or urethral stricture that may require any long-term instrumental treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stress urinary incontinence in women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

female stress incontinence Urinary Incontinence, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Nantes

    Nantes, France

  • Groupe Hospitalier Pitié-Salpêtrière

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.